Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026 Research and Development FDA, Gastrointestinal tract, Johnson & Johnson

Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De Novo classification from the US …
News

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026 Research and Development Psychiatry, ea pharma, schizophrenia

EA Pharma, a subsidiary of Eisai, has announced the initiation of a phase 3 clinical trial of evenamide, a schizophrenia …
News

Mavatar announces research collaboration with Sobi

January 6, 2026 Research and Development Immunology, Mavatar, Rare Diseases, sobi

Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …
News

DemeRx announces completion of alcohol use disorder treatment trial

January 5, 2026 Research and Development DemeRx, alcohol use disorder

DemeRx has announced the successful completion of its phase 1 study of DMX-1001 (oral noribogaine) in the treatment of alcohol …
News

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025 Research and Development Bio-Thera, Immunology, Stada

STADA and Bio-Thera’s Gotenfia (golimumab), a biosimilar of Janssen’s Simponi, has received a positive opinion from the European Medicines Agency …
News

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025 Regulatory Affairs, Research and Development Asthma & COPD, GSK

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …
News

Gilead’s HIV treatment meets primary trial endpoint

December 16, 2025 Research and Development Gilead, HIV/AIDS

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …
News

Evotec and Bayer announce new kidney disease study

December 11, 2025 Research and Development Bayer, Evotec, Nephrology

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …
News

EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy

December 10, 2025 Research and Development EpilepsyGTx, Neurology, epilepsy

EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …
News

Breast Cancer Now study to explore personalised drug doses

December 9, 2025 Research and Development Breast Cancer Now, Oncology

Breast Cancer Now has announced a new study to evaluate whether personalised drug doses could improve quality of life for …
News

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

December 8, 2025 Research and Development Neurology, UCB, epilepsy

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
News

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025 Research and Development Neurology, Teva, migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
News

Medicus Pharma shares updates on basal cell carcinoma trials

December 2, 2025 Research and Development Medicus Pharma, Oncology

Medicus Pharma has announced updates on the progress of SKNJCT-003 and SKNJCT-004, its clinical trials studying the efficacy of a …
News

Healing the fracture in the system: the case for universal fraction liaison services access

November 28, 2025 Medical Communications, Research and Development Osteoporosis

By Tina Backhouse In 2024, the UK government committed to achieving 100% coverage of Fracture Liaison Services (FLS)across the NHS …
Feature

Celltrion’s Remsima IV approved by EC in liquid form

November 27, 2025 Research and Development Celltrion Inc, Immunology

Celltrion’s Remsima IV, the first-ever liquid formulation of infliximab for autoimmune diseases, has been approved by the European Commission (EC). …
News
The Gateway to Local Adoption Series

Latest content

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026

SAH Diagnostics opens new diagnostics centre in Bristol

March 30, 2026